Autonomix Medical, Inc.

Autonomix Medical is a development-stage medical device enterprise focused on advancing diagnostic and therapeutic technologies for nervous system disorders. The company develops a catheter-based platform that combines high-sensitivity neural signal detection with targeted radiofrequency ablation, utilizing a "sense, treat, verify" approach to improve procedural precision. Its primary offerings comprise a proprietary microchip-enabled sensing catheter, an RF ablation catheter, a dedicated RF generator, and visualization software. Designed to navigate transvascular pathways, these systems target peripheral nerve fibers initially to manage pain associated with pancreatic cancer. The technology is tailored for interventional radiologists and cardiologists operating in hospital catheter laboratories, with potential future applications covering additional visceral pain conditions, hypertension, and other nerve-related disorders.

The company operates without commercial facilities or retail locations, functioning through prototype development, third-party manufacturing partnerships, and clinical trial sites. It maintains an international intellectual property portfolio covering technologies across the United States, Europe, Canada, Australia, China, India, Japan, Mexico, and Singapore. The provided report does not state the specific location of its corporate headquarters.

Summary of the business section of Autonomix Medical's latest annual report, written by StockData.

“As of March 31, 2025, we have 11 employees providing services to the Company, eight on a full-time basis and three on a part-time basis.”